Anti-Tumor Effects of Gilteritinib on FLT3 Mutations: Insights into Resistance Mechanisms in Ba/F3 Cell Models
These findings highlight the potent efficacy of gilteritinib against a wide range of <i>FLT3</i> mutations, including TKD-PM and JMD-PM, as well as those associated with resistance to quizartinib or midostaurin. This comparative analysis underscores the need for tailored therapeutic strategies in AML treatment, emphasizing the clinical significance of gilteritinib in overcoming drug resistance.
Authors
- Taku Yoshida (ORCID: https://orcid.org/0009-0002-8352-2594)
- Tatsuya Kawase (ORCID: https://orcid.org/0000-0003-2253-2238)
- Masamichi Mori
- Hirofumi Tsuzuki (ORCID: https://orcid.org/0009-0003-4042-3446)
- Taisuke Nakazawa
Institutions
- Astellas Pharma (Japan) (JP)
Publication Details
- Journal
- OncoTargets and Therapy
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/ott.s479519
- Citations
- 2
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 3.25
Funders
- Astellas Pharma
- Astellas Pharma Global Development